Vimedimex (VMD) Reprimanded by HoSE for Delayed 2025 Financial Explanations

Overview

HoSE reprimanded Vimedimex Pharmaceutical Joint Stock Company (VMD) for failing to publicly disclose required explanations alongside its audited 2025 financial statements by the April 15, 2026, deadline. The reprimand, issued via an official document, highlights governance and disclosure lapses despite the company reporting a 59.9% year-on-year increase in standalone net profit. The delay concerns explanations for the significant profit change and for audit qualifications related to unresolved asset issues.

Key Facts

• HoSE issued the reprimand on April 15, 2026, after receiving Vimedimex’s audited 2025 financial statements on April 13.
• Vimedimex’s 2025 standalone net profit reached over VND 34.7 billion, a 59.9% increase from 2024; consolidated net profit was over VND 42.4 billion, up 79.7%.
• The auditor issued a qualified opinion due to VND 198.9 billion in deposits blocked at VietinBank’s Quang Trung branch, related to the Citilight Tower project at 45 Võ Thị Sáu.
• Long-term receivables include approximately VND 1,578 billion from former leaders of the company and its subsidiaries, with recoverability not yet assessed.
• The Board of Directors is seeking guidance from the Ministry of Health to determine the actual capital contribution ratio for the Citilight project.
• The company had not evaluated the impact of these issues on its consolidated financial statements for the year ending December 31, 2025.

What Happened

According to an official document from the Ho Chi Minh City Stock Exchange (HoSE), Vimedimex Pharmaceutical (VMD) was reprimanded for not publishing required explanations for its audited 2025 financial statements by the stipulated deadline. HoSE received the company’s audited standalone and consolidated financial statements for 2025 on April 13, 2026. These statements showed substantial profit growth, with standalone net profit rising 59.9% year-on-year to over VND 34.7 billion. However, by April 15, Vimedimex had failed to disclose two mandatory explanations: one detailing the reasons for the more than 10% change in net profit compared to the prior year, and another addressing the auditor’s qualified opinion.

The auditor’s qualification stems from two primary issues. First, VND 198.9 billion in deposits at VietinBank’s Quang Trung branch remain blocked, related to investor cooperation for the Citilight Tower project. The Board of Directors is currently seeking clarification from the Ministry of Health to determine the actual capital contribution ratios, preventing a full assessment. Second, the company recorded approximately VND 1,578 billion in long-term receivables from former leaders and subsidiaries following a comprehensive capital and asset review. At the time of the audit report, Vimedimex had not assessed the recoverability of these amounts or their potential impact on the financial statements.

Market Context

Vimedimex (VMD) is listed on the Ho Chi Minh City Stock Exchange (HOSE) in the pharmaceuticals sector. The reprimand comes at a time when regulatory scrutiny on corporate governance and financial disclosure is increasing in Vietnam’s capital markets. While the company’s reported 2025 profit growth is notably strong, the audit qualifications and delayed explanatory disclosures introduce significant uncertainty. Investors typically view such regulatory actions and unresolved asset-quality issues as negative signals, potentially affecting market confidence and the stock’s valuation in the near term.

Strategic Significance

The reprimand underscores persistent governance and transparency challenges at Vimedimex that could impede its strategic execution. The unresolved VND 198.9 billion in blocked deposits ties up substantial capital, limiting financial flexibility for core pharmaceutical operations or expansion. More critically, the VND 1,578 billion in receivables from former leadership suggests potential historical governance failures and asset impairment risks. For long-term investors, the company’s ability to resolve these legacy issues, recover assets, and strengthen internal controls is crucial to realizing the underlying profitability indicated by its 2025 earnings growth.

What to Watch

• Vimedimex’s publication of the overdue explanations for profit changes and audit qualifications, including a clear timeline for resolution.
• Updates on the status of the VND 198.9 billion blocked deposits and the Ministry of Health’s guidance on the Citilight project capital structure.
• Progress in assessing the recoverability of the VND 1,578 billion in receivables and any potential write-downs in subsequent financial statements.
• Any further regulatory actions from HoSE or the State Securities Commission regarding compliance.
• The company’s Q1 2026 financial results and management commentary on addressing these disclosed issues.